Provided By GlobeNewswire
Last update: Aug 19, 2024
BOSTON, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, provided a business and financial update for the second quarter 2024.
NASDAQ:CUE (2/21/2025, 8:11:19 PM)
1.32
-0.05 (-3.65%)
Find more stocks in the Stock Screener